Blog

New Data Point Confirms Mark Zuckerberg's Jab at TikTok

TikTok's user base, which skews strongly toward younger demographics, continues to soar. The short-form music and karaoke app has emerged as a viable challenger to Facebook's (NASDAQ: FB) dominance

TheMotleyFool

0

Don’t Sleep on These 2 Pharmaceutical Stocks

It hasn't been a great year for pharma companies. The industry, as measured by the SPDR S&P Pharmaceuticals Index, is up less than 1.5% since the beginning of the year, a period during which the S&P

TheMotleyFool

0

2 Things Just Happened That Make Vertex Pharmaceuticals Stock a Screaming Buy

I've maintained for quite a while that Vertex Pharmaceuticals (NASDAQ: VRTX) is the best biotech stock on the market. My thinking was -- and is -- that Vertex's virtual monopoly in the cystic

TheMotleyFool

0

Will Investors Keep Paying a Premium for Wingstop?

Wingstop's (NASDAQ: WING) stock has more than quadrupled since its IPO in 2015 as the chicken wing chain has repeatedly impressed investors with its consistent same-store sales growth, aggressive

TheMotleyFool

0

Microsoft's Cloud Business Boosts Earnings

Expectations were high going into Microsoft's (NASDAQ: MSFT) earnings report. The company has stubbornly clung to its $1 trillion market cap, a watermark it achieved earlier this year. Microsoft has

TheMotleyFool

0

Livent's Move for Lithium Market Share Is Crushing Its Stock

Global lithium markets sure have been moody lately. On the one hand, the world will need to significantly increase production of lithium materials by the end of the 2020s to keep pace with soaring

TheMotleyFool

0

Are You Being Completely Honest About Your Job Skills?

If you're in the market for a new job, you're probably aware that a solid resume could be your ticket to an exciting offer. Specifically, the skills you detail on your resume could drive recruiters

TheMotleyFool

0

If Reelected, Would Trump Cut Social Security?

Ready or not, election season is beginning to ramp up, more than a full year ahead of the presidential election on Nov. 3, 2020. The future of a lot of programs and government spending is clearly on

TheMotleyFool

0

Christmas Creep, 2019 Edition: Big Retailers Extend Holiday Shopping Season Even Further

Just a few years ago, Black Friday still meant something. Some retailers might start displaying their Christmas decorations a bit earlier, but it wasn't until the day after Thanksgiving that they'd

TheMotleyFool

0

What's Behind Gilead Sciences' Lackluster Q3 Earnings Results

Has Gilead Sciences (NASDAQ: GILD) really turned the corner after several years of sinking revenue and earnings? That was the question for investors as the big biotech prepared to provide an update

TheMotleyFool

0

Why Investors Weren't Excited About Illumina's Q3 Earnings Beat

Illumina (NASDAQ: ILMN) downright disappointed investors with its second-quarter results in July, reporting slowing revenue growth and a year-over-year decline in adjusted earnings. However, CEO

TheMotleyFool

0

Is Novartis a Buy?

Pharmaceutical giant Novartis (NYSE: NVS) has seen a strong performance so far in 2019. While the company has been outperformed by rivals like Amgen, Novartis has edged out over other competitors

TheMotleyFool

0

How ResMed Blew Past Expectations With Its Q1 Results

Despite a horrible start, 2019 has turned out to be a reasonably good year so far for ResMed (NYSE: RMD). The healthcare company has consistently beaten Wall Street earnings estimates in recent

TheMotleyFool

0

What You'll Want to Know About Cerner's Solid Q3 Results

Cerner (NASDAQ: CERN) has quietly become a solid winner so far in 2019. Shares of the healthcare technology company are handily beating the broader market indexes. Cerner has met or beat Wall Street

TheMotleyFool

0